In:
Cancer, Wiley, Vol. 125, No. 24 ( 2019-12-15), p. 4380-4387
Kurzfassung:
Oncogenic driver mutations influence the disease course, treatment options, and development of brain metastases in patients with lung cancers. Results from this retrospective analysis of 498 patients with HER2 ‐, KRAS ‐, or EGFR ‐mutant lung cancers show that patients with HER2 ‐driven lung cancers have reduced overall survival and are at increased risk for developing brain metastases while they are on treatment.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v125.24
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2019
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1